Animal Fibrinogen Activity Assay: Principles, Methods, and Applications

Animal fibrinogen activity determination is a functional coagulation assay that quantifies the clot-forming capacity of fibrinogen in animal plasma or plasma-derived products. This testing is essential for veterinary clinical diagnostics, quality control of animal-derived fibrinogen used in surgical sealants and hemostatic products, and preclinical research. This article explains the underlying biochemistry, sample requirements, test items, analytical methods, and practical applications of fibrinogen activity measurement in animals.

Technical Overview

Fibrinogen (coagulation Factor I) is a soluble glycoprotein of approximately 340 kDa that is synthesized by hepatocytes and circulates in plasma at species-dependent concentrations, typically between 1.5 and 6 g/L. It functions as the terminal substrate of the coagulation cascade: thrombin cleaves fibrinopeptides A and B from the molecule, generating fibrin monomers that polymerize into a stable clot, which is then cross-linked by activated Factor XIII. Because this conversion is central to hemostasis, the measurement of functional fibrinogen activity is a cornerstone of coagulation testing.

It is important to distinguish between fibrinogen activity and fibrinogen antigen. Activity assays measure the actual clot-forming capability of the molecule in a clotting-based reaction, whereas immunological assays measure the total immunoreactive protein regardless of function. In conditions such as dysfibrinogenemia, liver disease, or after certain processing steps in plasma fractionation, antigen levels may be normal while functional activity is markedly reduced. For this reason, pharmacopoeial monographs and clinical guidelines emphasize functional, clot-based determination as the reference approach for potency assessment.

Animal fibrinogen activity determination covers a wide range of species and sample types, including citrated plasma from livestock and companion animals, animal-derived fibrinogen bulk substances used in fibrin sealants and tissue adhesives, and finished hemostatic medical devices. Testing is typically performed by accredited third-party laboratories or in-house quality control laboratories using validated clotting, spectrophotometric, or derived methods traceable to international reference materials.

Testing Samples

Citrated Plasma from Animal Species

The most common sample is platelet-poor citrated plasma, collected from blood drawn into 3.2% trisodium citrate at a 9:1 blood-to-anticoagulant ratio. Common species tested include bovine, porcine, ovine, equine, canine, feline, murine, rat, rabbit, and avian species. Blood should be centrifuged at 1,500–2,500 × g for 10–15 minutes within two hours of collection to obtain platelet-poor plasma, which minimizes interference from platelet-associated fibrinogen and clotting factors.

Plasma-Derived Fibrinogen Bulk Substances

Manufacturers of fibrin sealants, fibrin glue, and hemostatic agents source fibrinogen from animal (typically bovine or porcine) plasma through cryoprecipitation or ethanol fractionation. Bulk substances and in-process intermediates are tested for clottable protein content and functional activity to support batch release and process consistency.

Finished Products and Medical Devices

Fibrin sealant kits, collagen-based hemostatic dressings impregnated with fibrinogen, and absorbable hemostatic matrices require activity testing of the fibrinogen component before release and during stability studies to confirm that potency is maintained throughout the shelf life.

Research and Preclinical Samples

Plasma samples from animal models of thrombosis, sepsis, disseminated intravascular coagulation (DIC), hepatic injury, or inflammatory disease are analyzed to track disease progression or evaluate the effects of investigational compounds on the coagulation system in GLP-compliant safety studies.

• Sample volume: typically 0.5–1.0 mL of platelet-poor plasma per assay panel
• Storage: short-term at 2–8 °C (testing within 4–24 hours), long-term at −70 °C or below
• Shipping: frozen on dry ice with temperature monitoring; avoid repeated freeze–thaw cycles
• Rejection criteria: clotted samples, hemolyzed or severely lipemic plasma, incorrect anticoagulant ratio, prolonged unrefrigerated storage

Testing Items

Animal fibrinogen activity panels typically include the following measurable parameters, each of which addresses a different analytical question:

• Functional fibrinogen activity by the Clauss method (reported in g/L), the primary clinical and quality control assay
• Clottable protein content (pharmacopoeial method), expressing the percentage of total protein that is convertible to fibrin, used for bulk substance characterization
• PT-derived fibrinogen concentration, calculated from the optical change during prothrombin time testing
• Thrombin clotting time, an indirect indicator of fibrinogen function and polymerization kinetics
• Total fibrinogen antigen by immunoturbidimetric or nephelometric assay, used to calculate the activity-to-antigen ratio for detecting dysfibrinogenemia or processing damage
• Reptilase time, where applicable, to distinguish fibrinogen defects from heparin interference
• Stability-indicating activity assays at defined time points and storage conditions for product shelf-life evaluation

Testing Methods

Clauss Method (Functional Clotting Assay)

The Clauss method is the most widely accepted approach for functional fibrinogen activity. Plasma is diluted at least 1:10 with buffer to minimize the influence of other coagulation factors and inhibitors, and an excess of calibrated thrombin is added. The time from thrombin addition to clot formation is inversely proportional to the fibrinogen concentration. Results are calculated from a calibration curve generated with reference plasma traceable to the WHO International Standard for Fibrinogen. Clot detection may be optical or mechanical, and both automated coagulation analyzers and manual hook-timing techniques can be used.

PT-Derived Fibrinogen

During a prothrombin time assay, the change in optical density or viscosity as fibrin forms can be mathematically converted into an estimated fibrinogen concentration. This method is economical because it requires no additional reagents, but it is reagent-system dependent and less reliable at extremes of concentration. It is generally used as a screening tool, with abnormal results confirmed by the Clauss method.

Clottable Protein Method (Pharmacopoeial Reference Method)

For animal-derived fibrinogen bulk substances, pharmacopoeial monographs specify a clottable protein determination. The sample is clotted with thrombin under controlled conditions, the clot is harvested and washed repeatedly to remove entrapped non-clottable proteins, and the washed fibrin is dissolved in urea or alkaline solution. The protein content is then quantified spectrophotometrically at 280 nm or by nitrogen determination. The clottable protein fraction is expressed as a percentage of total protein and serves as the reference measure of potency for product release.

Immunological Assays (Supporting Determination)

Immunoturbidimetric and nephelometric assays quantify fibrinogen antigen using species-specific or cross-reactive antibodies. These methods are precise and rapid but do not provide functional information. They are valuable when combined with activity assays to calculate the activity-to-antigen ratio.

Method Validation and Quality Control

Whichever method is employed, accredited third-party laboratories and manufacturers validate performance characteristics in accordance with quality system requirements and, where applicable, ISO 17025 general competence criteria. Key validation parameters include:

• Linearity and reportable range across expected species concentration intervals
• Intra-run and inter-run precision, typically requiring coefficients of variation below 5–10% for clot-based assays
• Accuracy verified against reference plasma or pharmacopoeial reference procedures
• Interference assessment for heparin, fibrin degradation products, bilirubin, hemolysis, and lipemia
• Species-specific verification, since reference intervals and reagent responsiveness differ among animals

Each analytical run includes normal and abnormal control plasmas, calibration verification, and documented acceptability criteria before patient or product results are reported.

Applications

Veterinary Clinical Diagnostics

In veterinary medicine, fibrinogen activity is used to evaluate bleeding risk before surgery, to diagnose and monitor DIC, to assess hepatic synthetic failure, and to interpret prolonged clotting times. In ruminants and horses, fibrinogen is also a major acute-phase protein, so elevated activity indicates inflammatory conditions such as pneumonia, metritis, enteritis, and traumatic injury.

Biopharmaceutical Manufacturing

Fibrin sealants and tissue adhesives manufactured from animal plasma require documented fibrinogen activity and clottable protein content for batch release, process validation, and lot-to-lot consistency. Functional activity is a critical quality attribute that directly determines the adhesive and hemostatic performance of the final product.

Medical Device Evaluation

Hemostatic devices and blood-contacting products are evaluated within the framework of ISO 10993 biocompatibility testing, including ISO 10993-4 for interactions with blood. Fibrinogen activity measurement supports hemocompatibility assessment and the functional characterization of device coatings containing fibrinogen.

Preclinical Safety and Research Studies

Coagulation panels in GLP toxicology studies routinely include fibrinogen activity to detect compound-induced hypocoagulable or hypercoagulable states. Research applications include thrombosis models, sepsis pathophysiology, wound healing studies, fibrin polymerization kinetics, and the development of species-specific reference intervals.

FAQ

What is the difference between fibrinogen activity and fibrinogen antigen?

Activity assays measure how effectively fibrinogen forms a clot under the action of thrombin, while antigen assays measure the total amount of fibrinogen protein regardless of function. A low activity with normal antigen suggests dysfunctional fibrinogen, liver disease, or degradation products; both values together provide the most complete interpretation.

Why is citrated plasma required rather than serum or EDTA plasma?

Fibrinogen is consumed during serum formation, so serum cannot be used. EDTA chelates calcium and may interfere with thrombin-based reaction kinetics and analyzer clot detection. Trisodium citrate preserves fibrinogen in its functional state and is the standard anticoagulant for coagulation testing.

Can a single assay calibrated for human fibrinogen be used for all animal species?

Not directly. Fibrinogen concentrations, molecular characteristics, and clotting kinetics differ among species, and thrombin responsiveness varies. Laboratories must verify reagent performance for each species and, where possible, use species-appropriate reference plasmas or establish species-specific reference intervals.

What are typical reference intervals?

Reported intervals vary by study and method, but approximate plasma ranges include roughly 2–6 g/L in cattle, 2–4 g/L in horses, 1–4 g/L in dogs, 1.5–4 g/L in cats, 2–5 g/L in pigs, and 2–5 g/L in rats and mice. Each laboratory should establish or verify intervals for its own analytical system and animal population.

What interferences can affect activity results?

Common interferences include therapeutic heparin, elevated fibrin degradation products, very high or very low fibrinogen concentrations (antigen excess hook effect in immunological methods), severe hemolysis, lipemia, and hyperbilirubinemia. Dilution steps, heparin-neutralizing reagents, and confirmatory methods are used to manage these effects.

How long does testing take, and how should samples be submitted?

Standard turnaround is typically 3–7 working days once a properly collected, frozen platelet-poor plasma sample is received. Samples should be shipped frozen on dry ice with a chain-of-custody record, and product or bulk substance samples should be accompanied by the certificate of analysis target values and any relevant pharmacopoeial monograph requirements.